Biliary tract neoplasm

Related records

Broader conditions (16)

• Biliary tract disorder
• Cancer or benign tumor
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Endocrine gland neoplasm
• Endocrine system disorder
• Hepatobiliary disorder
• Hepatobiliary neoplasm
• Human disease
• Liver and intrahepatic bile duct neoplasm
• Liver disorder
• Neoplasm
• Neoplastic disease or syndrome

Narrower conditions (68)

• Adenocarcinoma of gallbladder and extrahepatic biliary tract
• Adenosquamous bile duct carcinoma
• Ampulla of vater adenocarcinoma
• Ampulla of vater adenosquamous carcinoma
• Ampulla of vater cancer
• Ampulla of vater clear cell adenocarcinoma
• Ampulla of vater mucinous adenocarcinoma
• Ampulla of vater neoplasm
• Ampulla of vater small cell neuroendocrine carcinoma
• Ampulla of vater squamous cell carcinoma
• Ampullary signet ring cell adenocarcinoma
• Bile duct adenocarcinoma
• Bile duct adenoma
• Bile duct cancer
• Bile duct carcinoma
• Bile duct carcinoma in situ
• Bile duct cystadenoma
• Bile duct mucinous cystic neoplasm with an associated invasive carcinoma
• Bile duct neoplasm
• Bile duct papillary neoplasm

Trials (471)

• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
• A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
• A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
• A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
• A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors
• A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
• A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
• A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
• A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
• A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
• A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
• A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Approved drugs (1)

• Zanidatamab

Drugs in development (37)

• Axitinib Phase 2
• Benmelstobart Phase 2
• Binimetinib Phase 3
• Capecitabine Phase 3
• Cediranib Phase 2
• Cetuximab Phase 2
• Cisplatin Phase 3
• CM-4307 Phase 2
• Docetaxel Phase 2
• Durvalumab Phase 3
• Encorafenib Phase 3
• Envafolimab Phase 2
• Fluorouracil Phase 3
• Futibatinib Phase 3
• Gemcitabine Phase 3
• Hydroxychloroquine Phase 2
• Ipilimumab Phase 2
• Irinotecan Phase 2
• Ivosidenib Phase 3
• Lenvatinib Phase 2